BiPar is the emerging leader in the repair of DNA (deoxyribonucleic acid), using inhibitors of the enzyme poly ADP-ribose polymerase (PARP). PARP inhibitors prevent cancer cells repair damaged DNA and cause his own death. BSI-201 (Phase II) is the main product of BiPar and could be the first drug of this new therapeutic class.
Under the agreement, the purchase price will depend on a series of installment payments related to the development of BSI-201. At best, could reach $ 500 million.
Takeda announced the creation of its subsidiary in Spain Japanese multinational Takeda
announced last week that it will open a subsidiary in Spain. Takeda Pharmaceutical Spain was initially dedicated to the promotion of drugs Blopress (candesartan cilexetil) and Glustin (pioglitazone HCl, known as Actos in Japan, USA and other European countries).
Casteleiro Ignacio Gonzalez has been appointed general manager company in Spain. Casteleiro González has over 16 years experience in the pharmaceutical industry and has worked in various therapeutic areas. Since 2008, he was director of the Business Unit of Virology, Bristol-Myers Squibb Spain.
Previously, he served as director of the Hospital Business Unit in the areas of Rheumatoid Arthritis and Pain, Onco-Hematology and Hepatitis, including supervision of sales and marketing teams.
Steve Webber, the new senior director of Research
Almirall Almirall Announces Appointment of Steve Webber as senior director of research, which will perform its work in the center of R & D of Almirall in Sant Feliu de Llobregat (Barcelona).
Steve Webber, Ph.D. in Pharmacology from University College of London, began (in 1992) his career in the pharmaceutical industry in Rhone-Poulenc Rorer (RPR), where he held various positions in the field of R & D to become vice president of Respiratory Diseases and rheumatologists in RPR / Aventis. His last position was vice president for Respiratory Biology Centre of Excellence for Drug Discovery at GSK Respiratory and Inflammation.
Under the agreement, the purchase price will depend on a series of installment payments related to the development of BSI-201. At best, could reach $ 500 million.
Takeda announced the creation of its subsidiary in Spain Japanese multinational Takeda
announced last week that it will open a subsidiary in Spain. Takeda Pharmaceutical Spain was initially dedicated to the promotion of drugs Blopress (candesartan cilexetil) and Glustin (pioglitazone HCl, known as Actos in Japan, USA and other European countries).
Casteleiro Ignacio Gonzalez has been appointed general manager company in Spain. Casteleiro González has over 16 years experience in the pharmaceutical industry and has worked in various therapeutic areas. Since 2008, he was director of the Business Unit of Virology, Bristol-Myers Squibb Spain.
Previously, he served as director of the Hospital Business Unit in the areas of Rheumatoid Arthritis and Pain, Onco-Hematology and Hepatitis, including supervision of sales and marketing teams.
Steve Webber, the new senior director of Research
Almirall Almirall Announces Appointment of Steve Webber as senior director of research, which will perform its work in the center of R & D of Almirall in Sant Feliu de Llobregat (Barcelona).
Steve Webber, Ph.D. in Pharmacology from University College of London, began (in 1992) his career in the pharmaceutical industry in Rhone-Poulenc Rorer (RPR), where he held various positions in the field of R & D to become vice president of Respiratory Diseases and rheumatologists in RPR / Aventis. His last position was vice president for Respiratory Biology Centre of Excellence for Drug Discovery at GSK Respiratory and Inflammation.
0 comments:
Post a Comment